-
Something wrong with this record ?
Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND)
C. Wittebrood, M. Boban, A. Cagnin, S. Capellari, FL. De Winter, A. Djamshidian, MM. González, LE. Hjermind, L. Krajcovicova, J. Krüger, J. Levin, K. Reetz, ER. Rodriguez, J. Rohrer, T. Van Langenhove, C. Reinhard, H. Graessner, R. Rusina, D....
Language English Country England, Great Britain
Document type Journal Article
NLK
PubMed Central
from 2024
ProQuest Central
from 2024-01-01
Health & Medicine (ProQuest)
from 2024-01-01
Wiley-Blackwell Open Access Titles
from 2024
PubMed
39447217
DOI
10.1111/ene.16446
Knihovny.cz E-resources
- MeSH
- Aggression drug effects MeSH
- Antipsychotic Agents therapeutic use MeSH
- Frontotemporal Dementia * drug therapy MeSH
- Impulsive Behavior drug effects MeSH
- Consensus MeSH
- Humans MeSH
- Selective Serotonin Reuptake Inhibitors therapeutic use MeSH
- Rare Diseases drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Europe MeSH
BACKGROUND AND PURPOSE: Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial-based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers. METHOD: The study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN-RND). RESULTS: The study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self-injury and self-harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases. CONCLUSIONS: The survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.
Centre for Rare Diseases University Hospital Tübingen Tübingen Germany
Centre of Excellence of Neurodegenerative Disease AP HP Pitié Salpêtrière Hospital Paris France
Department of Biomedical and Neuromotor Science University of Bologna Bologna Italy
Department of Medicine Universidad de Oviedo Oviedo Spain
Department of Neurology Cognitive Centre Ghent University Hospital Ghent Belgium
Department of Neurology Hospital Universitario Central de Asturias Oviedo Spain
Department of Neurology LMU University Hospital LMU Munich Munich Germany
Department of Neurology Medical University Innsbruck Innsbruck Tyrol Austria
Department of Neurology Neurocentre Oulu University Hospital Oulu Finland
Department of Neurology RWTH Aachen University Aachen Germany
Department of Neurology University Hospital Leuven Leuven Belgium
Department of Neuroscience and Padua Neuroscience Centre University of Padua Padua Italy
German Centre for Neurodegenerative Diseases Munich Germany
Institute for Medical Genetics and Applied Genomics University of Tübingen Tübingen Germany
Instituto de Investigación Sanitaria del Principado de Asturias Oviedo Spain
IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy
Medicine and Psychiatry Department University of Cantabria Santander Spain
MRC Oulu University Hospital Oulu Finland
Munich Cluster for Systems Neurology Munich Germany
Research Unit of Clinical Medicine University of Oulu Oulu Finland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003200
- 003
- CZ-PrNML
- 005
- 20250206104146.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/ene.16446 $2 doi
- 035 __
- $a (PubMed)39447217
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Wittebrood, Casper $u Department of Neurology, University Hospital Leuven, Leuven, Belgium $1 https://orcid.org/0009000426004736
- 245 10
- $a Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN-RND) / $c C. Wittebrood, M. Boban, A. Cagnin, S. Capellari, FL. De Winter, A. Djamshidian, MM. González, LE. Hjermind, L. Krajcovicova, J. Krüger, J. Levin, K. Reetz, ER. Rodriguez, J. Rohrer, T. Van Langenhove, C. Reinhard, H. Graessner, R. Rusina, D. Saracino, M. Houot, H. Seelar, R. Vandenberghe
- 520 9_
- $a BACKGROUND AND PURPOSE: Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial-based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers. METHOD: The study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN-RND). RESULTS: The study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self-injury and self-harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases. CONCLUSIONS: The survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a frontotemporální demence $x farmakoterapie $7 D057180
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a antipsychotika $x terapeutické užití $7 D014150
- 650 _2
- $a selektivní inhibitory zpětného vychytávání serotoninu $x terapeutické užití $7 D017367
- 650 _2
- $a vzácné nemoci $x farmakoterapie $7 D035583
- 650 _2
- $a agrese $x účinky léků $7 D000374
- 650 _2
- $a impulzivní chování $x účinky léků $7 D007175
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Boban, Marina $u Department of Cognitive Neurology, Referral Centre for Cognitive Neurology and Neurophysiology, University Hospital Centre Zagreb, Zagreb, Croatia $u School of Medicine, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Cagnin, Annchiara $u Department of Neuroscience and Padua Neuroscience Centre, University of Padua, Padua, Italy $1 https://orcid.org/0000000206354884
- 700 1_
- $a Capellari, Sabina $u Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy $u IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy $1 https://orcid.org/0000000316311439
- 700 1_
- $a De Winter, François-Laurent $u Department of Neurology, University Hospital Leuven, Leuven, Belgium
- 700 1_
- $a Djamshidian, Atbin $u Department of Neurology, Medical University Innsbruck, Innsbruck, Tyrol, Austria
- 700 1_
- $a González, Manuel Menéndez $u Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain $u Department of Medicine, Universidad de Oviedo, Oviedo, Spain $u Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
- 700 1_
- $a Hjermind, Lena E $u Department of Neuorology, Neurogenetics Clinic and Clinical Trial Unit, Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Krajcovicova, Lenka $u First Department of Neurology, St Anne ́s University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Krüger, Johanna $u Department of Neurology, Neurocentre, Oulu University Hospital, Oulu, Finland $u Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland $u MRC, Oulu University Hospital, Oulu, Finland
- 700 1_
- $a Levin, Johannes $u Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany $u German Centre for Neurodegenerative Diseases, Munich, Germany $u Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- 700 1_
- $a Reetz, Kathrin $u Department of Neurology, RWTH Aachen University, Aachen, Germany $1 https://orcid.org/0000000297309228
- 700 1_
- $a Rodriguez, Eloy Rodriguez $u Neurology Service, Marqués de Valdecilla University Hospital, Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain $u CIBERNED, Network Centre for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain $u Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
- 700 1_
- $a Rohrer, Jonathan $u Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK
- 700 1_
- $a Van Langenhove, Tim $u Department of Neurology, Cognitive Centre, Ghent University Hospital, Ghent, Belgium
- 700 1_
- $a Reinhard, Carola $u Centre for Rare Diseases and Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany
- 700 1_
- $a Graessner, Holm $u Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany $u Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
- 700 1_
- $a Rusina, Robert $u Department of Neurology, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Saracino, Dario $u Paris Brain Institute, Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, AP-HP-Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France $u Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP-Hôpital Pitié-Salpêtrière, Paris, France
- 700 1_
- $a Houot, Marion $u Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière Hospital, Paris, France $u Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France $u Clinical Investigation Centre for Neurosciences, Institut du Cerveau (ICM), Pitié-Salpêtrière Hospital, Paris, France
- 700 1_
- $a Seelar, Harro $u Department of Neurology and Alzheimer Centre Erasmus MC, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
- 700 1_
- $a Vandenberghe, Rik $u Department of Neurology, University Hospital Leuven, Leuven, Belgium
- 773 0_
- $w MED00001629 $t European journal of neurology $x 1468-1331 $g Roč. 31, č. 12 (2024), s. e16446
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39447217 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104142 $b ABA008
- 999 __
- $a ok $b bmc $g 2263131 $s 1239207
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 31 $c 12 $d e16446 $e 20241024 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
- LZP __
- $a Pubmed-20250121
